IDM Pharma Completes Sale of Non-Core Assets to Pharmexa A/S for $12 Million Cash
05-Jan-2006 -
IDM Pharma, Inc. announced it has completed the sale of specific assets related to its infectious disease programs and certain other assets to Pharmexa A/S for $12.0 million in cash. IDM will now focus its resources on its five clinical stage cancer programs.
In connection with the asset sale, ...
clinical trials
infectious diseases
license agreements
+1